LMX1B

protein-coding

LIM homeobox transcription factor 1 beta, the group of LIM class homeoboxes

Gene summary

This gene encodes a member of LIM-homeodomain family of proteins containing two N-terminal zinc-binding LIM domains, 1 homeodomain, and a C-terminal glutamine-rich domain. It functions as a transcription factor, and is essential for the normal development of dorsal limb structures, the glomerular basement membrane, the anterior segment of the eye, and dopaminergic and serotonergic neurons. Mutations in this gene are associated with nail-patella syndrome. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Mar 2010]

Previous symbols:
  • NPS1

MANE transcript

NM_001174147.2

Inheritance

AD

ClinVar variants

P:162U:181B:124

Top phenotype

Nail-patella syndrome; Focal segmental glomerulosclerosis 10

gnomAD constraint

pLI —, LoF o/e 0.18

Max pathogenic AF

—

Genomic locus

chr9:126,613,928-126,701,032

External References & Databases

Transcript & Mutation Effects

hg38 • Region Span ~87.1 kb
Loading mutation effect viewer...

GenCC Phenotypes & Disease Associations

Curated gene-disease validity assertions and inheritance patterns

nail-patella syndromeDEFINITIVE

Inheritance Pattern: AD

Disease ID:MONDO:0008061

Submitter: ClinGen

The LMX1B gene is located on chromosome 9 at 9q33.3 and encodes the LIM homeodomain transcription factor 1 beta, a transcription factor that plays a central role in cell differentiation during development. Mutations in LMX1B were first reported in relation to autosomal dominant nail-patella syndrome (NPS) in 1998 (Dreyer at al., 1998 PMID 9590287), although the first clinical description of the disorder was reported in 1933 (Turner JW, 1933 JAMA). The syndrome is characterised by a classic tetrad of congenital changes in the nails (absent, hypoplastic, or dystrophic), patellae (absent, small, or irregularly shaped), and elbows (limited range of motion), and the presence of iliac horns. Although not part of the classic tetrad, kidney disease and glaucoma also occur. While this disorder is highly penetrant, the expressivity of the clinical features is extremely variable both within and between families. More than 170 variants in LMX1B have been reported in NPS. onsense, frameshift, and splice site variants are observed throughout the entire gene, missense variants cluster predominantly in the LIM domains, and the the rest occur in the homeodomain. Partial and complete gene deletions have also been reported. 11 probands from 5 publications have been included in this curation (Dreyer at al., 1998 PMID 9590287; McIntosh et al., 1998 PMID 9837817; Sato et al., 2005 PMID 15774843; Bongers et al., 2008 PMID 18414507; Harita et al., 2020 PMID 32457516) to give a maximum score or 12 points for genetic evidence. . Additional evidence is available in the literature. This gene-disease association is also supported by experimental evidence, including animal models, expression studies, and in vitro functional assays. LMX1B was originally identified as a candidate gene for NPS due to the high degree of phenotypic similarity between lmx1b-knockout mice and humans with the disorder. Homozygous mice have absent patellae, absent nails, and renal abnormalities (Chen et al., 1998 PMID 9590288). Multiple studies examining the spatial and temporal expression pattern of LMX1B, using in situ hybridisation, have demonstrated its expression in the tissue types affected by NPS (Chen et al., 1998 PMID 9590288; Dreyer et al., 2000 PMID 10767331; Pressman et al., 2000 PMID 10660670). The mechanism of pathogenicity in NPS has been demonstrated to be loss of function, with mutated protein showing decreased or absent DNA binding ability and negligible transcriptional activity. No evidence has been observed to support a dominant-negative effect (Dreyer at al., 1998 PMID 9590287; Sato et al., 2005 PMID 15774843; Harita et al., 2020 PMID 32457516). Of note, variants in LMX1B have also been implicated in a renal-restricted nail-patella-like nephropathy. As per the criteria outlined by the ClinGen Lumping and Splitting Working Group, there was sufficient phenotypic variability and differences in the molecular mechanisms to support splitting these disorders into two distinct disease entities; nail-patella syndrome (OMIM: 161200) and focal segmental glomerulosclerosis 10 (OMIM:256020). Autosomal dominant focal segmental glomerulosclerosis 10 has therefore been curated separately. In summary, LMX1B is definitively associated with autosomal dominant nail-patella syndrome. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen Syndromic Disorders Gene Curation Expert Panel on the meeting date February 3rd, 2021 (SOP Version 8).

nail-patella syndromeSTRONG

Inheritance Pattern: AD

Disease ID:MONDO:0008061

Submitter: Labcorp Genetics (formerly Invitae)

nail-patella syndromeSTRONG

Inheritance Pattern: AD

Disease ID:MONDO:0008061

Submitter: PanelApp Australia

nail-patella syndromeDEFINITIVE

Inheritance Pattern: AD

Disease ID:MONDO:0008061

Submitter: G2P

nail-patella syndromeSUPPORTIVE

Inheritance Pattern: AD

Disease ID:MONDO:0008061

Submitter: Orphanet

nail-patella-like renal diseaseSUPPORTIVE

Inheritance Pattern: AD

Disease ID:MONDO:0009724

Submitter: Orphanet

Clinical Genomic Database (CGD)

Nail-patella syndrome; Focal segmental glomerulosclerosis 10AD

Manifestation: Dermatologic; Musculoskeletal; Ophthalmologic; Renal

Intervention: Ophthalmologic; Pharmacogenomic; Renal

Rationale: In Nail-patella syndrome, individuals may have open-angle glaucoma, and surveillance and appropriate treatment may be beneficial; Agents that may contribute to glaucoma (as well as NSAIDs as relates to renal function) should be avoided; Medical treatment (eg, ACE inhibitors) may be beneficial in terms of affecting the progression of renal disease; Renal transplantation has been described; In Focal segmental glomerulosclerosis, recognition of disease may allow early management, and renal transplant has been described

Comments: Onset may typically be during adulthood, though surveillance earlier may be warranted given reports of affected individuals in the 3rd decade

Refs: 9590287; 9618165; 15928687; 17515884; 18414507; 20301311; 21850167; 23687361; 32356190; 32791958Source: CGD (NHGRI)

ClinVar Associated Diseases & Phenotypes

Reported disease conditions connected to LMX1B variants in ClinVar

14 Conditions Cataloged
not providedTotal: 440
Nail-patella syndromeTotal: 151
Nail-patella-like renal diseaseTotal: 83
LMX1B-related disorderTotal: 69
Inborn genetic diseasesTotal: 58
not specifiedTotal: 48
Focal segmental glomerulosclerosisTotal: 4
Kidney disorderTotal: 2

ClinVar Variants & Pathogenicity by Type

Statistics based on transcript NM_001174147.2. Only rare variants are included.

We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.

Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.

EffectPLPVUSLBBSum
synonymous
5
clinvar
101
clinvar
3
clinvar
109
missense
20
clinvar
30
clinvar
171
clinvar
19
clinvar
240
nonsense
37
clinvar
8
clinvar
45
start loss
0
frameshift
34
clinvar
15
clinvar
1
clinvar
50
splice donor/acceptor (+/-2bp)
14
clinvar
4
clinvar
4
clinvar
1
clinvar
23
Total105571811213467

Highest pathogenic variant AF is 0.000038558144

Loading ClinVar variants...

Transcript Catalog

Annotated transcript isoforms across RefSeq and Ensembl databases

Showing 4 of 9 transcripts
Transcript IDSourceProtein IDCoding ExonsMANE Status
NM_001174147.2RefSeqNP_001167618.18MANE Select
ENST00000373474.9EnsemblENSP00000362573.38MANE Select
NM_001174146.2RefSeqNP_001167617.18Standard
NM_002316.4RefSeqNP_002307.28Standard

Model Organisms & Knockout Phenotypes

Observed phenotypic effects in mouse and zebrafish models

Gene / ModelOrganismObserved Phenotype
lmx1baDanio rerio

Structure: glutamatergic neuron

Quality: decreased amount

abnormal

Gene Ontology (GO) Annotations & Pathways

Biological processes, molecular functions, cellular components and pathways

Pathways ConsensusPathDB

  • Primary Focal Segmental Glomerulosclerosis FSGS
  • Dopaminergic Neurogenesis
  • Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways

Biological Process

  • in utero embryonic development
  • regulation of transcription, DNA-templated
  • multicellular organism development
  • dorsal/ventral pattern formation
  • neuron differentiation

Molecular Function

  • RNA polymerase II regulatory region sequence-specific DNA binding
  • DNA-binding transcription factor activity, RNA polymerase II-specific
  • DNA-binding transcription factor activity
  • protein binding
  • metal ion binding

Cellular Component

  • nucleus

gnomAD Constraint

Source: gnomAD

Gene type
protein_coding
Transcript type
protein_coding
Transcript
ENST00000355497
Coding exons
8
Length
86590
Individuals with no LoFs
125704
Homozygous LoFs
0
Heterozygous LoFs
3
Defined
125707
p
0.0000119
Z-ScoreObservedExpectedObserved/ExpectedMutation RateTotal Possible
Missense2.021692610.6480.00001682624
Missense (PolyPhen)4399.8720.430551013
Synonymous-0.8101281171.100.00000854759
Loss of Function3.56422.10.1810.00000120214

Population LoF Frequency

PopulationCAFp-valueStatus
African00.0absent
Latino/Admixed American0.0000880.000087rare
Ashkenazi Jewish00.0absent
East Asian00.0absent
Finnish00.0absent
European (Non-Finnish)00.0absent
South Asian00.0absent
Other00.0absent

dbNSFP Gene Annotations

Source: dbNSFP

Function
FUNCTION: Essential for the specification of dorsal limb fate at both the zeugopodal and autopodal levels.;

Recessive Scores

pRec
0.350

Intolerance Scores

LoFtool
0.0982
RVIS EVS
-0.85
RVIS percentile EVS
11.06

Essentials

Essential (CRISPR)
N
Essential (CRISPR2)
N
Indispensability pred.
E
Indispensability score
0.980

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium
For research and educational, non-commercial use only. Not for clinical or diagnostic use. GeneBe does not provide medical advice. Data use for AI modeling is prohibited: if used, the cost is $0.001 per byte of downloaded uncompressed data.